Ramya Raghupathi, MD
Epilepsy · Philadelphia, PANPI 1720334113
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (56.0%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. UCB, Inc. accounts for 61.9% of it on its own, with 10 other manufacturers making up the rest. 2025 is the largest year on record at $7,602, more than ten times the $21 reported in 2019.
Across 53 payments — averaging $263.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$9K
- Jazz Pharmaceuticals Inc.$1K
- Neuropace, Inc.$976
- DIXI Medical USA Corp$824
- Aquestive Therapeutics, Inc.$660
- SK Life Science, Inc.$559
- plus $1K from 5 others
What the payments were for
- Consulting fees$7,80556%
- Speaking & faculty fees$3002%
- Travel & lodging$2,23816%
- Food & beverage$3,59926%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 15 | $8,631 |
| Jazz Pharmaceuticals Inc. | 9 | $1,256 |
| Neuropace, Inc. | 9 | $976 |
| DIXI Medical USA Corp | 1 | $824 |
| Aquestive Therapeutics, Inc. | 1 | $660 |
| SK Life Science, Inc. | 9 | $559 |
| Neurelis, Inc. | 5 | $508 |
| Livanova USA, Inc. | 1 | $300 |
| Greenwich Biosciences, Inc. | 1 | $150 |
| Acadia Pharmaceuticals Inc | 1 | $57 |
| Amgen | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Fintepla$8,219
- Epidiolex$1,231
- RNS Neurostimulator Kit$621
- VALTOCO$430
- VNS Therapy$300
- XCOPRI$117
How this compares
$13,942 in reported general payments places this provider in the 80th percentile of 28 epilepsy providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XcopriCenobamate | 71 | $91,361 |
| LamictalLamotrigine | 44 | $44,602 |
| BriviactBrivaracetam | 21 | $37,423 |
| OnfiClobazam | 15 | $34,218 |
| TrileptalOxcarbazepine | 18 | $19,900 |
| Lacosamide | 156 | $19,314 |
| Rufinamide | 16 | $13,981 |
| Clobazam | 123 | $13,538 |
| NayzilamMidazolam | 16 | $12,112 |
| Oxcarbazepine | 81 | $11,544 |
| Levetiracetam | 173 | $8,438 |
| Lamotrigine ErLamotrigine | 11 | $6,443 |
| Divalproex Sodium | 45 | $5,082 |
| Carbamazepine ErCarbamazepine | 35 | $2,896 |
| Zonisamide | 53 | $2,594 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| SK Life Science, Inc.Xcopri | $559 | $91,36171 claims |
| UCB, Inc.Briviact, Nayzilam | $8,631 | $49,53537 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 28 epilepsy providers in Pennsylvania.
Other epilepsy in Philadelphia
- Kathryn DavisPhiladelphia$59K
- Michael GelfandPhiladelphia$50K
- Saurabh SinhaPhiladelphia$21K
- Erin ConradPhiladelphia$3K
- Taneeta GangulyPhiladelphia$2K
- Catherine KulickPhiladelphia$2K
- Genna WaldmanPhiladelphia$2K
- Itai LoushyPhiladelphia$845
- Daniel ZhouPhiladelphia$658
- Brian LittPhiladelphia$384
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.